Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Midea Group Co., Ltd.
美的集團股份有限公司
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 0300)

(1) RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND (2) PROPOSED APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR

RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The board (the "**Board**") of directors (the "**Directors**") of Midea Group Co., Ltd. (the "**Company**", together with its subsidiaries, the "**Group**") hereby announces that it has received a written resignation report from Dr. Qiu Lili (邱鋰力) ("**Dr. Qiu**") on 29 April 2026. Due to career planning reasons, Dr. Qiu intended to resign from her positions as an independent non-executive Director of the fifth session of the Board, and a member of the audit committee, the remuneration and evaluation committee, the nomination committee and the strategy committee of the Company, with effect from the date on which the new independent non-executive Director is elected at the next general meeting of the Company.

Dr. Qiu has confirmed that she has no disagreement with the Board and there are no other matters relating to her resignation that need to be brought to the attention of the shareholders of the Company (the "**Shareholders**"). Before her resignation becomes effective, Dr. Qiu will continue to perform her duties as an independent non-executive Director and a member of the various special committees of the Board of the Company in accordance with relevant requirements. After her resignation becomes effective, Dr. Qiu will no longer hold any position within the Company.

The Board would like to express its sincere gratitude to Dr. Qiu for her contributions to the Company during her tenure as an independent non-executive Director.

PROPOSED APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The Board further announces that on 29 April 2026, the Board considered and approved the relevant resolution to nominate Dr. Zhang Ya (張婭) ("**Dr. Zhang**") as a candidate for independent non-executive Director of the fifth session of the Board of the Company. The appointment of Dr. Zhang is subject to the consideration and approval at the general meeting of the Company. The term of office of Dr. Zhang shall commence from the date of approval at the general meeting of the Company and end upon the expiration of the term of the fifth session of the Board. Upon her election as an independent non-executive Director at the general meeting, Dr. Zhang will succeed Dr. Qiu to serve as a member of the audit committee, the remuneration and evaluation committee, the nomination committee and the strategy committee of the Company, with a term of office consistent with her term as an independent non-executive Director of the fifth session of the Board. Subject to the approval of Dr. Zhang's appointment at the general meeting, the Company will enter into a service agreement with her, and her remuneration will be determined with reference to her duties and responsibilities and the prevailing market conditions. The Board proposes to fix the annual director's remuneration of Dr. Zhang at RMB450,000 (tax inclusive).

The biographical details of Dr. Zhang are set out as follows:

Zhang Ya, female, aged 47, Ph.D., is currently the vice dean of the School of Artificial Intelligence and the executive vice dean of the Institute of Medical Artificial Intelligence (醫學人工智能研究院) of Shanghai Jiao Tong University, where she also serves as a distinguished professor of the university. She has been selected into the National High-level Talent Program. Dr. Zhang previously served as an assistant professor (Tenure-track) in the Department of Electrical Engineering and Computer Science at the University of Kansas in the United States, and as a research engineering manager and technical lead at the U.S. headquarters of Yahoo! Inc., accumulating extensive experience in both academic research and industrial practice. She has long been dedicated to the interdisciplinary field of artificial intelligence and healthcare, having led numerous major national scientific research projects. She has achieved a series of significant advancements in fundamental theoretical innovation and clinical translation applications of medical artificial intelligence, possessing profound academic attainments and outstanding technological innovation capabilities.

Dr. Zhang has confirmed that: (i) she has satisfied all the independence criteria as set out in Rules 3.13(1) to (8) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**"); (ii) she has no financial or other interest in the business of the Group, past or present, and has no connection with any core connected persons (as defined in the Listing Rules) of the Company; and (iii) there are no other factors that may affect her independence. The Board and the nomination committee of the Board are also of the view that Dr. Zhang meets the independence criteria for independent non-executive directors as set out in Rule 3.13 of the Listing Rules and consider her to be independent of the Company.

Dr. Zhang has not held any directorship in any other listed companies in the past three years. Dr. Zhang does not hold any position in any member of the Group, nor have any connection with any other Directors, senior management, substantial Shareholders or controlling Shareholders of the Company. Furthermore, as at the date of this announcement, Dr. Zhang does not have any interest in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Save as disclosed above, there is no other information relating to the proposed appointment of Dr. Zhang that is required to be disclosed pursuant to Rules 13.51(2)(h) to (v) of the Listing Rules, nor are there any other matters that need to be brought to the attention of the Shareholders.

According to the board diversity policy and the nomination policy of the Company, and the recommendation of the nomination committee of the Board, the Board has proposed to elect Dr. Zhang as an independent non-executive Director after comprehensively taking into account her educational background, knowledge, skills, experience and the contribution she can make to the Board. Having reviewed Dr. Zhang's professional suitability for serving as an independent non-executive Director, the Board and the nomination committee of the Board are of the view that, as described in her biography set out in this announcement, her appointment will bring valuable perspectives, knowledge, skills and experience to the Board to ensure the efficient and effective operation of the Board, and will facilitate the Board to achieve diversity, which is conducive to the compliant operation and healthy and sustainable development of the Company.

The proposed appointment of Dr. Zhang as an independent non-executive Director of the fifth session of the Board of the Company is subject to consideration at the general meeting of the Company. A circular containing, among other things, details of the proposed appointment of the independent non-executive Director together with the notice of the general meeting will be published on the website of the Company (www.midea.com.cn) and the website of The Stock Exchange of Hong Kong Limited (www.hkexnews.hk) in due course.

By order of the Board
Midea Group Co., Ltd.
Mr. Fang Hongbo
Chairman, Executive Director and Chief Executive Officer

Hong Kong, 29 April 2026

As at the date of this announcement, the Board comprises: (i) Mr. Fang Hongbo, Mr. Wang Jianguo, Dr. Gu Yanmin, Mr. Guan Jinwei and Dr. Zhang Tian as executive Directors; (ii) Mr. Zhao Jun as non-executive Director; and (iii) Dr. Xu Dingbo, Dr. Xiao Geng, Dr. Liu Qiao and Dr. Qiu Lili as independent non-executive Directors.